RETRACTED: In vitro simulation of the liver first-pass effect with biotransformation-competent HepG2 cells to study effects of MG-132 on liver and cancer cells
Clinical Hemorheology and Microcirculation · 2024
DOI: 10.3233/ch-238108 ↗Kurz gefasst
Zurückgezogene Publikation in der Zeitschrift Clinical Hemorheology and Microcirculation, 2024. Verfasst von Sarah Kammerer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biotechnology, Brandenburg University of Technology Cottbus-Senftenberg, Senftenberg, Germany. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Neoplasms, Leupeptins. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND: Liver biotransformation is the major route for drug metabolism in humans, often catalysed by cytochrome P450 (CYP) enzymes. This first-pass effect can lead to hepatotoxicity and influences the bioavailability of drugs. OBJECTIVE: We aimed to establish in vitro culture systems simulating the liver first-pass to study effects of the proteasome inhibitor MG-132 simultaneously on hepatocytes and cancer cells. METHODS: The first-pass effect was simulated by conditioned medium transfer (CMT) from pre-treated HepG2 CYP3A4-overexpressing cells to either pancreatic cancer cell line PANC-1 or primary colon cancer cells, and by indirect co-culture (CC) of liver and cancer cells in a shared medium compartment. Experimental proteasome inhibitor MG-132 was used as test substance as it is detoxified by CYP3A4. RESULTS: Cancer cells showed higher viabilities in the first-pass simulation by CMT and CC formats when compared to monocultures indicating effective detoxification of MG-132 by HepG2 CYP3A4-overexpressing cells. HepG2-CYP3A4 cells showed reduced viabilites after treatment with MG-132. CONCLUSIONS: We successfully established two different culture systems to simulate the liver first-pass effect in vitro. Such systems easily allow to study drug effects simultaneously on liver and on target cancer cells. They are of great value in pre-clinical cancer research, pharmaceutical research and drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biotechnology, Brandenburg University of Technology Cottbus-Senftenberg, Senftenberg, Germany.
- MVZ Gemeinschaftslabor Cottbus, Cottbus, Germany.
- Department of General Surgery, University Hospital Brandenburg, Brandenburg Medical School Theodor Fontane, Brandenburg an der Havel, Germany.
Zitieren
APA
Kammerer, S., Nowak, E., Mantke, R., Jung, F., & Küpper, J. H. (2024). RETRACTED: In vitro simulation of the liver first-pass effect with biotransformation-competent HepG2 cells to study effects of MG-132 on liver and cancer cells. Clinical Hemorheology and Microcirculation. https://doi.org/10.3233/ch-238108
Vancouver
Kammerer S, Nowak E, Mantke R, Jung F, Küpper JH. RETRACTED: In vitro simulation of the liver first-pass effect with biotransformation-competent HepG2 cells to study effects of MG-132 on liver and cancer cells. Clinical Hemorheology and Microcirculation. 2024. doi:10.3233/ch-238108
BibTeX
@article{Kammerer2024,
author = {Kammerer, Sarah and Nowak, Elisabeth and Mantke, René and Jung, Friedrich and Küpper, Jan-Heiner},
title = {RETRACTED: In vitro simulation of the liver first-pass effect with biotransformation-competent HepG2 cells to study effects of MG-132 on liver and cancer cells},
journal = {Clinical Hemorheology and Microcirculation},
year = {2024},
doi = {10.3233/ch-238108}
}
EUVIMED